Each lot of this antibody is quality control tested by immunocytochemistry. For immunocytochemistry, a concentration range of 2.5 - 10 μg/mL?is recommended. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor? 594 has an excitation maximum of 590 nm, and a maximum emission of 617 nm.

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections^4,6,7 and formalin-fixed paraffin-embedded sections¹¹, immunoprecipitation¹, activation of T cells^2,3,5, Western blotting⁹, and spatial biology (IBEX)^16,17. The LEAF? purified antibody (Endotoxin < 0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 300413, 300414, and 300432). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 300437, 300438, 300465, 300466, 300473, 300474) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin < 0.01 EU/?g).

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

View more applications data for this product in our Scientific Poster Library.

1. Salmeron A, et al. 1991. J. Immunol. 147:3047. (IP)
2. Graves J, et al. 1991. J. Immunol. 146:2102. (Activ)
3. Lafont V, et al. 2000. J. Biol. Chem. 275:19282. (Activ)
4. Ryschich E, et al. 2003. Tissue Antigens 62:48. (IHC)
5. Thompson AG, et al. 2004. J. Immunol. 173:1671. (Activ)
6. Sakkas LI, et al. 1998. Clin. Diagn. Lab. Immun. 5:430. (IHC)
7. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
8. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
9. Van Dongen JJM, et al. 1988. Blood 71:603. (WB)
10. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
11. Pollard, K. et al. 1987. J. Histochem. Cytochem. 35:1329. (IHC)
12. Luckashenak N, et al. 2013. J. Immunol. 190:27. PubMed
13. Laurent AJ, et al. 2014. PLoS One. 9:103683. PubMed
14. Li J, et al. 2015. Cancer Res. 75:508. PubMed
15. Stoeckius M, et al. 2017. Nat. Methods. 14:865-868. (PG)
16. Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
17. Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed

1. Emmons TR, et al. 2021. Cancer Immunol Res. 9:790. PubMed
2. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
3. Su Y, et al. 2021. Cancers (Basel). 13:. PubMed

Mature T and NK T cells, thymocyte differentiation

1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
3. Lanier L, et al. 1986. J. Immunol. 137:2501-2507.